摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-甲基萘-2-甲醛 | 35699-45-7

中文名称
1-甲基萘-2-甲醛
中文别名
——
英文名称
1-Methyl-2-naphthaldehyde
英文别名
1-Methylnaphthalene-2-carboxaldehyde;1-methylnaphthalene-2-carbaldehyde
1-甲基萘-2-甲醛化学式
CAS
35699-45-7
化学式
C12H10O
mdl
——
分子量
170.211
InChiKey
UZUIHIHIXOLGDL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

SDS

SDS:aa8871646e9de9464e33ac1f1ca7a139
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1,4-二碘苯1-甲基萘-2-甲醛 在 palladium diacetate 、 silver trifluoroacetate溶剂黄146聚甘氨酸 作用下, 以 为溶剂, 反应 36.0h, 以32%的产率得到1,1'-(1,4-phenylenebis(methylene))bis(2-naphthaldehyde)
    参考文献:
    名称:
    通过瞬态导向基团合成多环芳烃(PAHs)
    摘要:
    在这项工作中,开发了一种有效的合成路线来构建具有各种形状,宽度和边缘拓扑的PAH。PAHs的前体是通过芳烃的直接芳基化,通过瞬时配体定向的C–H官能化策略获得的,并且通过使用Brønsted酸催化剂可以轻松实现环芳烃化。这种新颖的途径为以高效方式建立PAH提供了机会。
    DOI:
    10.1021/acs.orglett.8b03359
  • 作为产物:
    描述:
    1-甲基-2-萘甲酰氯 在 Pd-BaSO4 、 xylene 作用下, 生成 1-甲基萘-2-甲醛
    参考文献:
    名称:
    Synthesis of 3, 6-Dimethyl-2, 3-dihydro-1H-cyclopent[a]anthracene. A Possible Dehydrogenation Product of Anthranoid Rearrangement Product of Steroids
    摘要:
    DOI:
    10.1246/bcsj.32.1202
点击查看最新优质反应信息

文献信息

  • Pretreatment compositions
    申请人:Powell B. David
    公开号:US20060286484A1
    公开(公告)日:2006-12-21
    A pretreatment composition of: (a) at least one compound having structure VI V 1 —Y—V 2 VI wherein Y is selected from the group consisting of S, O, NR 2 , (HOCH) p , and each R 1 is independently selected from H, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group or a halogen, each R 2 is independently H, SH, CH 3 , C 2 H 5 , and a linear or branched C 1 -C 4 alkyl group containing a thiol group; and wherein V 1 and V 2 are independently selected from wherein, m is independently an integer from 0 to 4 with the proviso that m can =0 only when Y═ n is an integer from 1 to 5; p is an integer of from 1 to 4, and each R 1 is defined as above; (b) at least one organic solvent, and optionally, (c) at least one adhesion promoter; wherein the amount of the compound of Structure VI present in the composition is effective to inhibit residue from forming when the photosensitive composition is coated on a substrate and the coated substrate is processed to form an image thereon.
    预处理组合物包括:(a)至少一种具有结构VIV1—Y—V2VI的化合物,其中Y选自S、O、NR2、(HOCH)p和each R1,每个R1独立选自H、烷基、烯基、炔基、烷氧基或卤素,每个R2独立为H、SH、CH3C2H5和含巯基的直链或支链C1-C4烷基;其中V1和V2独立选自,其中m独立为0到4的整数,条件是m只能为0当Y=n为1到5的整数;p为1到4的整数,每个R1如上定义;(b)至少一种有机溶剂,以及可选地(c)至少一种促进粘附的物质;其中,组合物中存在的结构VI化合物的量足以抑制光敏组合物涂布在基材上并在涂覆的基材上形成图像时形成残留物。
  • Evidence for the Intracomplex Reaction in Gattermann−Koch Formylation in Superacids:  Kinetic and Regioselectivity Studies
    作者:Mutsuo Tanaka、Masahiro Fujiwara、Qiang Xu、Yoshie Souma、Hisanori Ando、Kenneth K. Laali
    DOI:10.1021/ja9641012
    日期:1997.6.1
    in HF−SbF5 provided crucial evidence in favor of intracomplex reaction via a third-order rate equation, [ArH][ArH2+SbF6-][CO], where the formylation electrophile HCO+ is generated by CO protonation by the arenium ion. Dependence of regioselectivity on substrate, superacid, and SbF5/substrate molar ratio showed that high para regioselectivity stems from intracomplex reaction and the observed regioselectivity
    报告了间二甲苯、1-甲基萘甲苯在 HF-SbF5 和 CF3SO3H-SbF5 中 Gattermann-Koch 甲酰化的动力学和区域选择性数据,作为 SbF5/底物摩尔比的函数。HF-SbF5 中间二甲苯甲酰化的动力学研究提供了支持通过三级速率方程 [ArH][ArH2+SbF6-][CO] 进行内部络合反应的关键证据,其中甲酰化亲电试剂 HCO+ 由 CO 产生由离子质子化。区域选择性对底物、超强酸和 SbF5/底物摩尔比的依赖性表明,高对位区域选择性源于络合物内反应,观察到的区域选择性反映了络合物内反应与常规反应之间的比率。Gattermann-Koch 甲酰化和使用 HCOF 的 Friedel-Crafts 甲酰化之间区域选择性的比较表明,区域选择性趋势不反映亲电试剂的性质,而是反应途径;Friedel-Crafts 甲酰化似乎也具有内...
  • Cascade reaction for the synthesis of polycyclic aromatic hydrocarbons via transient directing group strategy
    作者:Ziqi Wang、Wendan Dong、Bing Sun、Qinqin Yu、Fang-Lin Zhang
    DOI:10.1016/j.tet.2019.06.036
    日期:2019.7
    A Pd(II)-catalyzed cascade synthesis of diverse polycyclic aromatic hydrocarbons via transient directing group strategy has been developed, involving the consecutive arylation, cyclization and aromatization. The efficiency and practicality were demonstrated by wide substrate range, concise synthetic pathway and mild reaction conditions. The subsequent transformations of the benz[a]anthracene core accessed
    已经开发了一种通过Pd(II)催化的通过瞬态导向基团策略级联的多种多环芳烃,涉及连续的芳基化,环化和芳构化。广泛的底物范围,简明的合成途径和温和的反应条件证明了其效率和实用性。苯并[ a ]核心的后续转化获得了天然的生物活性PAH分子。
  • PYRROL-1-YL BENZOIC ACID DERIVATIVES USEFUL AS MYC INHIBITORS
    申请人:DANA-FARBER CANCER INSTITUTE, INC.
    公开号:US20150291521A1
    公开(公告)日:2015-10-15
    The present invention provides compounds of Formula (I-A), (I-B), and (I-C), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting Myc (e.g., c-Myc) activity. The present invention further provides methods of using the compounds described herein for treating Myc-mediated disorders (e.g., cancer and other proliferative diseases). The present invention also provides assays for identifying Myc inhibitors.
    本发明提供了公式(I-A)、(I-B)和(I-C)的化合物,其药学上可接受的盐以及其制药组合物。本发明的化合物可用于抑制Myc(例如c-Myc)的活性。本发明还提供了使用本文所描述的化合物治疗Myc介导的疾病(例如癌症和其他增殖性疾病)的方法。本发明还提供了用于鉴定Myc抑制剂的检测方法。
  • A composition for increasing the anti-cancer activity of an anti-cancer compound
    申请人:OTSUKA PHARMACEUTICAL CO., LTD.
    公开号:EP0180188A2
    公开(公告)日:1986-05-07
    A composition for increasing the anti-cancer activity of an anti-cancer compound selected from among 5-fluorouracil and a compound capable of producing 5-fluorouracil in vivo, the composition comprising an effective amount of a pyridine derivative represented by the formula wherein R1 is hydroxy or acyloxy, R2 and R4 are each hydrogen, halogen, amino, carboxyl, carbamoyl, cyano, nitro, lower alkyl, lower alkenyl or lower alkoxycarbonyl, R3 and R are each hydrogen, hydroxy or acyloxy; when at least one of R1, R3 and R5 is hydroxy, the structure of 1-position on the pyridine rina can be duetothe due to the keto-enol tautomerism, said hydrogen attached to nitrogen being optionally substituted with a substituent selected from the group consisting of lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, phthalidyl, carbamoyl, lower alkoxycarbonyl-lower alkylcarbamoyl, phenyl-lower alkoxy-lower alkyl, phenylcarbamoyl which may have a substituent on the phenyl ring, lower alkylcarbamoyl, carboxy-lower alkylcarbamoyl, lower alkylthio-lower alkyl and lower alkenyl, provided that the compound having the following formula is excluded, wherein a is hydrogen, lower alkyl, tetrahydrofuranyl, tetrahydropyranyl, lower alkoxy-lower alkyl, lower alkylcarbamoyl, lower alkylthio-lower alkyl or lower alkenyl.
    一种提高选自5-尿嘧啶和一种能在体内产生5-尿嘧啶的化合物的抗癌活性的组合物,该组合物包括有效量的由式表示的吡啶衍生物 其中 R1 是羟基或酰氧基,R2 和 R4 分别是氢、卤素、基、羧基、基甲酰基、基、硝基、低级烷基、低级烯基或低级烷氧基羰基,R3 和 R 分别是氢、羟基或酰氧基;当 R1、R3 和 R5 中至少有一个是羟基时,吡啶里纳上 1 位的结构可以是 当 R1、R3 和 R5 中至少有一个是羟基时,吡啶里纳上 1 位的结构可以是酮烯醇同分异构,所述连接到氮上的氢可选择被选自低烷基、四氢呋喃基、四氢吡喃基、低烷氧基低烷基、邻苯二甲酰基基甲酰基、低烷氧基羰基低烷基基甲酰基组成的取代基取代、苯基-低级烷氧基-低级烷基、苯基基甲酰基(苯基环上可能有取代基)、低级烷基基甲酰基、羧基-低级烷基基甲酰基、低级烷基-低级烷基和低级烯基,但具有下式的化合物除外、 其中 a 为氢、低级烷基、四氢呋喃基、四氢呋喃基、低级烷氧基低级烷基、低级烷基基甲酰基、低级烷基低级烷基或低级烯基。
查看更多